Minimum order quantity: 10 Box
Indications for use PALBOCICLIB is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer: – in combination with an aromatase inhibitor; – in combination with fulvestrant in women previously receiving endocrine therapy. In pre-or perimenopausal women, endocrine therapy should be combined with aluteinization. Hormone Releasing Hormone (LHRH) agonists.
| Features | Specification |
| Packaging Size | 1*120 |
| Composition | Abiraterone Acetate (250mg) |
| Brand | Zelgor 250mg Tablet |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Shelf life | 3 YEAR |
| Therapeutic Uses | Prostate cancer |
){kind=link}